Publications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (14)

2024

  1. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 774-792

2023

  1. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

  3. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 4, pp. 294-306

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

  3. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2018

  1. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the use of tiopurines in inflammatory bowel disease

    Gastroenterologia y Hepatologia

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301

2015

  1. Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients

    Current Pharmacogenomics and Personalized Medicine, Vol. 13, Núm. 1, pp. 61-67

  2. Fecal calprotectin in ileal Crohn's disease: Relationship with magnetic resonance enterography and a pathology score

    Inflammatory Bowel Diseases, Vol. 21, Núm. 7, pp. 1572-1579

2013

  1. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

    Pharmacogenomics, Vol. 14, Núm. 6, pp. 631-640